Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

FOXK2 Transcription Factor and Its Emerging Roles in Cancer.

Nestal de Moraes G, Carneiro LDT, Maia RC, Lam EW, Sharrocks AD.

Cancers (Basel). 2019 Mar 20;11(3). pii: E393. doi: 10.3390/cancers11030393. Review.

2.

Full-length osteopontin and its splice variants as modulators of chemoresistance and radioresistance (Review).

Gimba ERP, Brum MCM, Nestal De Moraes G.

Int J Oncol. 2019 Feb;54(2):420-430. doi: 10.3892/ijo.2018.4656. Epub 2018 Dec 6. Review.

PMID:
30535434
3.

IKZF1 deletion and co-occurrence with other aberrations in a child with chronic myeloid leukemia progressing to acute lymphoblastic leukemia.

Klumb CE, Barbosa TDC, Nestal de Moraes G, Schramm MT, Emerenciano M, Maia RC.

Pediatr Blood Cancer. 2019 Apr;66(4):e27570. doi: 10.1002/pbc.27570. Epub 2018 Dec 4.

PMID:
30511400
4.

SUMOylation modulates FOXK2-mediated paclitaxel sensitivity in breast cancer cells.

Nestal de Moraes G, Ji Z, Fan LY, Yao S, Zona S, Sharrocks AD, Lam EW.

Oncogenesis. 2018 Mar 13;7(3):29. doi: 10.1038/s41389-018-0038-6.

5.

11a-N-Tosyl-5-deoxi-pterocarpan, LQB-223, a novel compound with potent antineoplastic activity toward breast cancer cells with different phenotypes.

Lemos LG, Nestal de Moraes G, Delbue D, Vasconcelos Fda C, Bernardo PS, Lam EW, Buarque CD, Costa PR, Maia RC.

J Cancer Res Clin Oncol. 2016 Oct;142(10):2119-30. doi: 10.1007/s00432-016-2212-6. Epub 2016 Aug 12.

6.

Erratum to: In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs.

Khongkow P, Middleton AW, Wong JP, Kandola NK, Kongsema M, de Moraes GN, Gomes AR, Lam EW.

Methods Mol Biol. 2016;1395:E1. doi: 10.1007/978-1-4939-3347-1_18. No abstract available.

PMID:
27488409
7.

In Vitro Methods for Studying the Mechanisms of Resistance to DNA-Damaging Therapeutic Drugs.

Khongkow P, Middleton AW, Wong JP, Kandola NK, Kongsema M, de Moraes GN, Gomes AR, Lam EW.

Methods Mol Biol. 2016;1395:39-53. doi: 10.1007/978-1-4939-3347-1_3. Erratum in: Methods Mol Biol. 2016;1395:E1. Middleton, Anna K [corrected to Middleton, Anna W].

8.

FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance.

Nestal de Moraes G, Delbue D, Silva KL, Robaina MC, Khongkow P, Gomes AR, Zona S, Crocamo S, Mencalha AL, Magalhães LM, Lam EW, Maia RC.

Cell Signal. 2015 Dec;27(12):2496-505. doi: 10.1016/j.cellsig.2015.09.013. Epub 2015 Sep 25.

PMID:
26404623
9.

Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance.

Nestal de Moraes G, Bella L, Zona S, Burton MJ, Lam EW.

Curr Drug Targets. 2016;17(2):164-77. Review.

10.

FOXM1: an emerging master regulator of DNA damage response and genotoxic agent resistance.

Zona S, Bella L, Burton MJ, Nestal de Moraes G, Lam EW.

Biochim Biophys Acta. 2014 Nov;1839(11):1316-22. doi: 10.1016/j.bbagrm.2014.09.016. Epub 2014 Oct 5. Review.

11.

The pterocarpanquinone LQB-118 induces apoptosis in acute myeloid leukemia cells of distinct molecular subtypes and targets FoxO3a and FoxM1 transcription factors.

Nestal de Moraes G, Castro CP, Salustiano EJ, Dumas ML, Costas F, Lam EW, Costa PR, Maia RC.

Int J Oncol. 2014 Nov;45(5):1949-58. doi: 10.3892/ijo.2014.2615. Epub 2014 Aug 21.

PMID:
25174716
12.

FOXM1: A key oncofoetal transcription factor in health and disease.

Bella L, Zona S, Nestal de Moraes G, Lam EW.

Semin Cancer Biol. 2014 Dec;29:32-9. doi: 10.1016/j.semcancer.2014.07.008. Epub 2014 Jul 25. Review.

PMID:
25068996
13.

Phosphorylated Crkl reduction levels are associated with the lowest P-glycoprotein activity levels in cells from chronic myeloid leukemia patients.

Vasconcelos FC, Nestal de Moraes G, Moellmann-Coelho A, Maia RC.

Leuk Res. 2013 Dec;37(12):1711-8. doi: 10.1016/j.leukres.2013.09.021. Epub 2013 Sep 29.

PMID:
24210993
14.

Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels.

Nestal de Moraes G, Vasconcelos FC, Delbue D, Mognol GP, Sternberg C, Viola JP, Maia RC.

Eur J Cell Biol. 2013 Aug-Sep;92(8-9):247-56. doi: 10.1016/j.ejcb.2013.08.001. Epub 2013 Aug 31.

PMID:
24064045
15.

XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells.

Silva KL, de Souza PS, Nestal de Moraes G, Moellmann-Coelho A, Vasconcelos Fda C, Maia RC.

Leuk Res. 2013 Oct;37(10):1350-8. doi: 10.1016/j.leukres.2013.06.014. Epub 2013 Jul 25.

16.

The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia.

Nestal de Moraes G, Souza PS, Costas FC, Vasconcelos FC, Reis FR, Maia RC.

Leuk Res Treatment. 2012;2012:671702. doi: 10.1155/2012/671702. Epub 2012 Apr 24.

17.

P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells.

Souza PS, Vasconcelos FC, De Souza Reis FR, Nestal De Moraes G, Maia RC.

Int J Oncol. 2011 Oct;39(4):925-33. doi: 10.3892/ijo.2011.1103. Epub 2011 Jun 28.

PMID:
21720708
18.

Immunodetection of caspase-3 by Western blot using glutaraldehyde.

Nestal de Moraes G, Carvalho É, Maia RC, Sternberg C.

Anal Biochem. 2011 Aug 15;415(2):203-5. doi: 10.1016/j.ab.2011.04.032. Epub 2011 Apr 27.

PMID:
21596015
19.

Survivin overexpression correlates with an apoptosis-resistant phenotype in chronic myeloid leukemia cells.

Nestal de Moraes G, Silva KL, Vasconcelos FC, Maia RC.

Oncol Rep. 2011 Jun;25(6):1613-9. doi: 10.3892/or.2011.1224. Epub 2011 Mar 22.

PMID:
21431279

Supplemental Content

Loading ...
Support Center